10-Q: Bausch Health Q3 2025: Revenue Up 7%, Debt Refinanced

Bausch Health reports strong Q3 2025 revenue growth of 7% to $2.681 billion, driven by Bausch + Lomb, Salix, and Solta Medical segments, alongside significant debt refinancing activities.

Summary

• Revenue for the three months ended September 30, 2025, increased by 7% to $2,681 million, compared to $2,510 million in the prior year period.
• Operating income for Q3 2025 was $619 million, a significant increase from $318 million in Q3 2024.
• Net income attributable to Bausch Health Companies Inc. for Q3 2025 was $179 million, a favorable change from a net loss of $85 million in Q3 2024.
• For the nine months ended September 30, 2025, revenue grew 6% to $7,470 million, up from $7,066 million in the same period of 2024.
• Operating income for the nine months ended September 30, 2025, was $1,339 million, an increase from $988 million in the prior year period.
• Net income attributable to Bausch Health Companies Inc. for the nine months ended September 30, 2025, was $269 million, compared to a net loss of $139 million in the same period of 2024.
• The company completed April 2025 Refinancing Transactions, extending approximately $6,870 million in aggregate debt maturities from 2025-2028 to 2030-2032.
• Bausch + Lomb completed its June 2025 Refinancing Activity, including an $800 million revolving credit facility and a new $2,325 million term B loan facility.
• Repurchased and retired $602 million of 9.25% Senior Unsecured Notes in August 2025.
• The $300 million AR Credit Facility was repaid and terminated on October 27, 2025, resulting in no debt maturities until 2027.
• Acquired DURECT Corporation in September 2025 for $84 million, adding Larsucosterol, a drug candidate with FDA Breakthrough Therapy designation for alcohol-associated hepatitis.
• Bausch + Lomb acquired Whitecap Biosciences in January 2025 for $28 million and Elios Vision in December 2024 for $99 million upfront, expanding its eye health pipeline and glaucoma treatment portfolio.
• Xifaxan has been selected for the Medicare drug price negotiation program, with an initial price applicability in 2027, expected to negatively impact sales revenue in that year.
• Ongoing Xifaxan Generics Litigation, with the Norwich First ANDA approval enjoined until October 2029.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant revenue and income growth, coupled with successful debt refinancing efforts that improved its capital structure. Strategic acquisitions and pipeline advancements also contribute positively. However, ongoing legal challenges, the impact of healthcare reform on Xifaxan pricing, and the IOL recall present headwinds. The overall sentiment is positive due to the strong financial turnaround and proactive debt management.

Positives

• Strong revenue growth of 7% in Q3 2025 and 6% in 9M 2025, driven by Bausch + Lomb, Salix, and Solta Medical segments.
• Significant improvement in operating income and net income for both the quarter and nine-month periods, moving from losses to profitability.
• Successful April 2025 Refinancing Transactions extended $6.87 billion in debt maturities to 2030-2032, significantly improving the capital structure and liquidity profile.
• Repurchase and retirement of $602 million in senior unsecured notes and termination of the $300 million AR Credit Facility further reduced debt and extended maturities, with no debt maturities until 2027.
• Strategic acquisitions of DURECT Corporation, Whitecap Biosciences, and Elios Vision bolster the company's pipeline in gastroenterology and eye health, adding innovative therapies and expanding market presence.
• Larsucosterol, acquired with DURECT, holds FDA Breakthrough Therapy designation, indicating potential for significant clinical impact.
• Positive legal outcomes in the Norwich I Xifaxan Litigation prevent generic entry until October 2029, protecting a key revenue stream.
• Settlement and dismissal of several Xifaxan generic lawsuits (Carnegie, Zydus, SABA, Mylan, Alkem) reduce legal uncertainties.
• Settlement of the Lumify DRL lawsuit provides a clear market entry date of June 30, 2027, for generic drops.
• Settlement of the Blackrock Canadian Claims and the New Mexico Attorney General Consumer Protection Action resolves significant legal matters.

Negatives

• Interest expense increased by $66 million in Q3 2025 and $156 million in 9M 2025, primarily due to higher effective interest rates on refinanced debt.
• Bausch + Lomb announced a voluntary recall of certain enVista IOL products in March 2025 due to raw material issues, impacting cost of goods sold and segment profit.
• Xifaxan's selection for the Medicare drug price negotiation program is expected to negatively impact sales revenue in 2027.
• The International segment experienced a revenue decrease of 2% in Q3 2025 and 1% in 9M 2025, primarily due to lower volumes in Latin America and unfavorable foreign currency impacts.
• The Diversified segment's revenue decreased by 4% in Q3 2025 and 6% in 9M 2025, mainly due to lower volumes in Neurology and Dermatology businesses.
• Bausch + Lomb segment profit decreased by 9% in 9M 2025, attributed to higher selling and promotional expenses (e.g., MIEBO) and the impact of the enVista IOL recall.
• Ongoing legal challenges persist for products like Trulance and Cabtreo, as well as broader generic pricing antitrust litigation.
• The company's decision to cease participation in the Medicaid Drug Rebate Program (MDRP) and 340B Drug Pricing Program, despite expanded patient assistance, introduces uncertainty regarding future patient access and reimbursement dynamics.

Risks

• Substantial debt and the ability to reduce outstanding debt levels, along with compliance with financial covenants in senior notes indentures and credit agreements, pose ongoing financial risks.
• The completion, timing, structure, and expected benefits of the Bausch + Lomb Separation remain uncertain, with potential for business disruption, dissynergy costs, and impacts from the Xifaxan Generics Litigation.
• Ongoing and potential future legal proceedings, including securities class actions, antitrust litigation, intellectual property disputes (e.g., Xifaxan, Trulance, Cabtreo, Lumify), and product liability claims, are costly, time-consuming, and could materially adversely affect the business.
• The introduction of generic, biosimilar, or other competitors for key branded products (e.g., Aplenzin, Bryhali, Relistor Subcutaneous, Xifaxan, Jublia) following loss of exclusivity could significantly decrease product sales.
• Regulatory oversight, inspections, and compliance with legal and regulatory requirements by agencies like the FDA and Health Canada are continuous, with potential for adverse actions.
• Healthcare reform measures, particularly the Inflation Reduction Act (IRA) and state-level price controls, could reduce drug prices and reimbursement levels, negatively impacting revenues and operating results, as seen with Xifaxan's price negotiation.
• Macroeconomic factors such as heightened inflation, interest rates, slower growth, potential recession, trade policies, tariffs, and foreign currency exchange volatility could adversely impact revenues, expenses, and margins.
• Geopolitical conflicts, including the Russia-Ukraine war and the Middle East conflict, could affect economic and global financial markets, supply chains, and regional sales.
• The voluntary recall of enVista IOL products highlights risks associated with manufacturing, quality control, and third-party supplier standards.
• Challenges in integrating acquired companies, businesses, and products, and realizing the expected benefits of acquisitions like DURECT, Whitecap Biosciences, and Elios Vision, could impact financial performance.
• The ability to retain, motivate, and recruit executives and other key employees is crucial for business continuity and strategic execution.
• Interruptions, breakdowns, or breaches in information technology systems could disrupt business operations.
• Risks associated with climate change could impact operations and supply chains.

Future Outlook

The company expects top-line results for its rifaximin SSD-40IR Phase 3 studies by early 2026 and plans to initiate a registrational Phase 3 program for Larsucosterol in early 2026. The launch of enVista Beyond TM (extended depth of focus) in the U.S. is anticipated in early 2027. The negotiated price for Xifaxan with CMS, effective January 1, 2027, is expected to negatively impact sales revenue for Xifaxan in 2027. The company anticipates generic competition for Aplenzin (2026), Bryhali (2026), Relistor Subcutaneous (2028), Xifaxan (2028) in the U.S., and Jublia (2028) in Canada. Management expects to remain in compliance with financial maintenance covenants and meet debt service obligations for the next twelve months and continues to evaluate opportunities for operational streamlining and cost savings globally.

Management Comments

• "We continue to believe that the B+L Separation... makes strategic sense."
• "We continue to evaluate all relevant factors and considerations related to the B+L Separation, including the Xifaxan Generics Litigation."
• "We continue to execute on actions intended to bring out value in our Company, which includes focus on our capital structure."
• "The April 2025 Refinancing Transactions reduced our short term cash requirements for debt service by extending approximately $6,870 million in aggregate debt maturities from the years 2025 through 2028 to the years 2030 through 2032. This provides us more flexibility to operate and allows us to more effectively allocate capital to initiatives that will strengthen our products and brands."
• "With the paydown of our AR Credit Facility, we have no debt maturities until 2027."
• "We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan."
• "Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy."
• "Our goal is to maintain a straightforward process to ensure continuity of care for patients, physicians and caregivers during this transition [from MDRP/340B]."
• "We remain confident in the strength of the Xifaxan patents and intend to vigorously defend its intellectual property."
• "We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum."

Industry Context

The pharmaceutical and medical device industries continue to navigate significant challenges, including evolving healthcare reforms like the Inflation Reduction Act (IRA) impacting drug pricing, persistent generic competition, and complex patent litigation. Macroeconomic factors such as inflation, rising interest rates, and geopolitical instability (e.g., Russia-Ukraine, Middle East conflicts) add layers of complexity, affecting global supply chains and market conditions. Bausch Health's strategic acquisitions in specialized areas like eye health (Elios Vision, Whitecap Biosciences) and gastroenterology (DURECT) reflect a broader industry trend towards strengthening core portfolios and pipeline development to drive future growth. The voluntary recall of enVista IOLs underscores the inherent manufacturing and quality control risks prevalent in the medical device sector. The company's decision to discontinue participation in certain federal drug pricing programs (MDRP, 340B) while expanding patient assistance programs is a strategic response to the dynamic reimbursement landscape and a move to manage pricing complexities.

Management Changes

Corporate Governance

Legal Proceedings

• **U.S. Securities Litigation Opt-Out Litigation**: Settled 36 of 37 opt-out cases; Hound Partners Offshore Fund, LP is the sole remaining matter.
• **U.S. Securities Litigation Kelk Complaint**: District Court granted motion to dismiss amended complaint without prejudice; Plaintiffs filed a second amended complaint, motion to dismiss pending.
• **Derivative Lawsuit Powers Complaint**: Stayed as of January 23, 2024.
• **Canadian Securities Litigation Opt-Out Litigation**: Blackrock Canadian Claims settled in April 2025 and concluded in May 2025. CalSTRS and The Bank of Korea et al. v. Valeant Pharmaceuticals International, Inc. et al. proceedings are ongoing.
• **Canadian Securities Litigation Ren Statement of Claim**: Putative class action filed December 23, 2024, motion for leave to pursue pending.
• **Hound Partners Lawsuit**: Currently stayed.
• **Generic Pricing Antitrust Litigation (MDL 2724)**: Company and subsidiaries are defendants in multidistrict antitrust litigation; Bausch + Lomb Corporation removed as defendant. State of Connecticut case remanded to U.S. District Court for District of Connecticut. Cases pending in Philadelphia County and New York State Supreme Court. Canadian class proceeding (Kathryn Eaton v. Teva Canada Limited, et al.) ongoing.
• **Xifaxan Antitrust Litigation**: Four antitrust complaints filed in U.S. District Court for District of Rhode Island between September and October 2025, alleging unlawful 2018 patent settlement with Actavis.
• **Xifaxan Paragraph IV Proceedings**: Norwich I Xifaxan Litigation affirmed by Federal Circuit, preventing FDA approval of Norwich First ANDA until October 2029. Norwich II Xifaxan Litigation appealed to DC Circuit, oral argument scheduled for December 11, 2025. Amneal Xifaxan Litigation ongoing with 30-month stay. Ajanta Xifaxan Litigation: Notice received October 6, 2025, company intends to file suit. Carnegie, Zydus, SABA, Mylan, Alkem lawsuits settled and dismissed in 2025. Cipla settlement agreement executed October 15, 2025.
• **MSN Trulance Paragraph IV Proceedings**: 3-day bench trial to begin November 10, 2025.
• **Cabtreo Paragraph IV Proceedings**: Company filed suit in March 2025, triggering 30-month stay.
• **Xifaxan Litigation with Curia IP Holdings, LLC**: Consolidated lawsuits alleging infringement of Curia Patents, with stipulations of non-infringement entered for several patents. Company continues to defend.
• **Zaxine Notice of Allegation in Canada**: Company filed Statement of Claim against Sandoz Canada in March 2025.
• **Lumify Paragraph IV Proceedings DRL, Somerset & Gland**: DRL Lawsuits settled July 9, 2025, with market entry date of June 30, 2027. Somerset and Gland ANDA lawsuits filed in April 2025, triggering 30-month stays.
• **Vyzulta and Lotemax SM**: Ongoing infringement proceedings against potential generic competitors.
• **Inter Partes Review Proceedings (Trulance)**: Federal Circuit vacated PTAB decision and remanded for additional fact-finding regarding 786 Patent.
• **Shower to Shower Products Liability Litigation**: 23 suits pending, with Johnson & Johnson having indemnification obligations. LTL/Red River bankruptcy cases dismissed.
• **U.S. Securities Litigation New Jersey Declaratory Judgment Lawsuit**: Settlement reached in early August 2025, case stayed, expected to be dismissed in January 2026.
• **Doctors Allergy Formula Lawsuit**: Trial set for April 2026.
• **Apriso Qui Tam Litigation**: Company filed motion to dismiss third amended complaint, pending.
• **Rifaximin Breach of Contract Litigation**: Settled and dismissed with prejudice June 4, 2025.
• **PreserVision AREDS Patent Litigation**: All proceedings closed, last matter dismissed April 10, 2025.
• **New Mexico Attorney General Consumer Protection Action**: Settlement with Johnson & Johnson, Company and affiliates released, consent judgment entered May 5, 2025.

Stakeholder Impact

• **Shareholders**: Positive financial results, debt reduction, and strategic acquisitions could enhance shareholder value. The approval of the Shareholder Rights Plan aims to protect shareholder interests. However, ongoing B+L separation uncertainties and legal risks create potential volatility.
• **Employees**: Restructuring and integration costs, including employee severance, indicate potential impacts on workforce. Share-based compensation plans are in place to align employee incentives.
• **Customers/Patients**: The voluntary recall of enVista IOLs directly impacts patients. The expanded Patient Assistance Program for Medicaid-eligible patients aims to maintain access to therapies, mitigating the impact of discontinuing participation in MDRP and 340B programs. Pricing changes and generic competition will affect product affordability and availability.
• **Creditors**: Successful debt refinancing and reduction of short-term maturities improve the company's credit profile and ability to meet obligations. Continued compliance with debt covenants is critical.
• **Suppliers**: The enVista IOL recall led to enhanced inspection protocols and more explicit standards for monomer preparation by vendors, indicating increased scrutiny on supplier quality.

Next Steps

• Complete the full B+L Separation, subject to targeted debt leverage ratios and applicable shareholder and other necessary approvals.
• Continue to evaluate all relevant factors and considerations related to the B+L Separation, including the Xifaxan Generics Litigation.
• Expect top-line results for rifaximin SSD-40IR Phase 3 studies by early 2026.
• Plan to start a registrational Phase 3 program for Larsucosterol in early 2026.
• Review the European Medicines Agency's September 2025 response to the Clear + Brilliant Touch submission and await final response from Chinese authority for registration.
• Initiate a Lumify next generation clinical study.
• Continue the European launch of LuxLife Trifocal IOL and the Canadian launch of enVista Aspire.
• Expect U.S., Europe, Singapore, and Hong Kong launches for enVista Envy.
• Anticipate the U.S. launch of enVista Beyond TM (extended depth of focus) in early 2027.
• Continue to evaluate opportunities to streamline operations and identify additional cost savings globally.
• Continue to monitor the capital structure and evaluate financing alternatives.
• The negotiated price for Xifaxan with CMS will come into effect on January 1, 2027.
• Jury selection for the Doctors Allergy Formula Lawsuit is scheduled to begin on April 20, 2026, with the trial set for April 24 to May 8, 2026.
• Oral argument for the Norwich II Xifaxan DC Circuit appeal is scheduled for December 11, 2025.
• A 3-day bench trial for the MSN Trulance Paragraph IV Proceedings is set to begin on November 10, 2025.
• The company intends to file suit against Ajanta Pharma Limited for Xifaxan patent infringement within 45 days of receiving the Notice of Paragraph IV Certification.
• Shareholders will be asked to reconfirm the Shareholder Rights Plan (SRP) at every third annual meeting thereafter.

Key Dates

Recommendation

Bausch Health has demonstrated a strong financial turnaround in Q3 and 9M 2025, transitioning from net losses to significant net income. The company's proactive debt management, including substantial refinancing and debt reduction, has significantly improved its capital structure and extended maturities, providing greater financial flexibility. Strategic acquisitions are bolstering the product pipeline and market presence, particularly with the addition of Larsucosterol, which holds FDA Breakthrough Therapy designation. While ongoing legal challenges and the anticipated impact of the IRA on Xifaxan pricing are notable headwinds, the company's robust pipeline, commitment to innovation, and efforts to improve patient access position it for sustainable long-term growth. The overall positive trajectory and strategic initiatives suggest a favorable outlook for investors.

Keywords

Bausch Health, Bausch + Lomb, Pharmaceuticals, Medical Devices, 10-Q, Financial Results, Debt Refinancing, Xifaxan, Lumify, DURECT, Larsucosterol, Glaucoma, Acne, Dry Eye, IOLs, Patent Litigation, Antitrust, Healthcare Reform, Inflation Reduction Act, Capital Structure, Shareholder Rights Plan, Specialty Pharma, Eye Health